Literature DB >> 7575072

Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection.

W T Caiaffa1, N M Graham, N Galai, R T Rizzo, K E Nelson, D Vlahov.   

Abstract

OBJECTIVE: To evaluate stability of delayed-type hypersensitivity (DTH) skin test over time in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative injecting drug users.
METHOD: A community-based cohort of injecting drug users who had serial skin testing with purified protein derivative tuberculin, mumps, and Candida albicans antigen. Delayed-type hypersensitivity anergy was defined as a skin test result of less than 3 mm for all three antigens; DTH positivity was a skin test result of 3 mm or greater for at least one antigen (Centers for Disease Control and Prevention, Atlanta, Ga, 1993).
RESULTS: At baseline, 36% of HIV-seropositive subjects (n = 401) were anergic as compared with 14% of HIV-seronegative subjects (n = 552; P < .001). During follow-up, fewer HIV-seropositive subjects remained DTH positive (42%) and more remained anergic (19%) than of HIV-seronegative subjects (67% and 7%, respectively). Twenty-four percent of HIV-seropositive subjects who were initially DTH positive became anergic as compared with 15.3% of the HIV-seronegative subjects. However, the proportion changing from anergy to DTH positivity was greater among HIV-seropositive subjects (15%) than HIV-seronegative subjects (12%). In comparison to those who remained DTH positive, HIV-seropositive subjects with CD4 cell counts of less than 0.50 x 10(9)/L (odds ratio = 6.4) and less than 0.35 x 10(9)/L (odds ratio = 11.2) were more likely to remain anergic than those who had CD4 cell counts above 0.50 x 10(9)/L or were HIV seronegative.
CONCLUSIONS: Although the prevalence and incidence of DTH anergy were higher in HIV-seropositive subjects, high rates of change in DTH status occurred in both directions. This suggests that instability of DTH skin testing is substantial and only partially dependent on HIV status. Although a single test may be an unreliable indicator of HIV-induced immunosuppression, two consecutive anergic readings were strongly associated with a CD4 cell count below 0.50 x 10(9)/L and particularly below 0.35 x 10(9)/L. For determining false negativity of tuberculin tests, persistent DTH anergy is more reliable than a single test among HIV-seropositive injecting drug users. Anergy testing appears to be unnecessary with CD4 cell counts greater than 0.5 x 10(9)/L.

Entities:  

Mesh:

Year:  1995        PMID: 7575072

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis.

Authors:  R C Hendrickson; J F Douglass; L D Reynolds; P D McNeill; D Carter; S G Reed; R L Houghton
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection.

Authors:  Luigi Codecasa; Paola Mantegani; Laura Galli; Adriano Lazzarin; Paolo Scarpellini; Claudio Fortis
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus.

Authors:  A S Rogers; J H Ellenberg; S D Douglas; L Henry-Reid; L Peralta; C M Wilson
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

Authors:  Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2007-01-11       Impact factor: 21.405

5.  Clinical investigation: increased serum stromal derived factor 1 alpha levels in pulmonary tuberculosis.

Authors:  K Mizuno; W Matsuyama; H Mitsuyama; M Watanabe; I Higashimoto; M Osame; K Arimura
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.

Authors:  D C Perlman; M N Gourevitch; C Trinh; N Salomon; L Horn; D C Des Jarlais
Journal:  J Urban Health       Date:  2001-09       Impact factor: 3.671

7.  Dendritic cell recruitment in response to skin antigen tests in HIV-1-infected individuals correlates with the level of T-cell infiltration.

Authors:  Frank Liang; Emily Bond; Kerrie J Sandgren; Anna Smed-Sörensen; Molebogeng X Rangaka; Christoph Lange; Richard A Koup; Grace A McComsey; Michael M Lederman; Robert J Wilkinson; Jan Andersson; Karin Loré
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

8.  Interferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden country.

Authors:  Clíona Ní Cheallaigh; Ian Fitzgerald; Jacinta Grace; Gurmit Jagjit Singh; Nahla El-Eraki; Noel Gibbons; Joseph Keane; Thomas R Rogers; Susan Clarke; Colm Bergin
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

9.  Diagnosing latent tuberculosis infection in the HIV era.

Authors:  Philippe H Lagrange; Jean Louis Herrmann
Journal:  Open Respir Med J       Date:  2008-05-23

10.  Cutaneous anergy in pregnant and nonpregnant women with human immunodeficiency virus.

Authors:  N L Eriksen; A W Helfgott
Journal:  Infect Dis Obstet Gynecol       Date:  1998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.